Oral presentation highlighting data from 15 subjects from the OraGrowtH212 study supporting the conclusions of the preliminary data analysis
Baseline characteristics of OraGrowtH210 study subjects highlighted in poster presentation
AUSTIN, Texas, March 5, 2023 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. LUMOa biopharmaceutical company advancing an oral therapeutic candidate for pediatric growth hormone deficiency (PGHD) through Phase 2 clinical trials, announced today that additional data from its OraGrowtH212 study has been included in an oral presentation of interim results at 2023 International Meeting of Pediatric Endocrinology (IMPE)which took place from March 4th to 7th, 2023 in Buenos Aires, Argentina. Data from the interim analysis of its OraGrowtH210 study will also be presented as a poster during the conference.
“The additional data presented at IMPE on our OraGrowtH212 study supports the conclusions we drew from the interim analysis of the data we performed last November on the PK/PD profile of LUM-201″ , said Rick Hawkins, Chairman and CEO of Lumos Pharma. “The data update continued to show a dose-dependent increase in growth hormone pulsatility, a correlation of pulsatility with increased altitude velocity, and a sustained response through 12 months. Now that the OraGrowtH210 and OraGrowtH212 studies are fully enrolled, we look forward to completing these studies and reporting top-line results in Q4 2023.”
Oral presentation
title – Dose-dependent increase in GH AUC12:00 a.m. – 12:00 p.m with LUM-201 in pediatric GH deficiency (iPGHD) from the preliminary analysis data of the OraGrowtH212 study
Lead Author – Fernando Cassorla, MD, Chief of Pediatric Endocrinology, University of Chile
Date/Time – Sunday, March 5, 3:15 p.m. – 4:00 p.m. local time
Slide presentation available in Posters & Publications Section of the Lumos Pharma website
The OraGrowtH212 study is an open-label, single-site study evaluating the pharmacokinetic (PK) and pharmacodynamic (PD) effects of oral LUM-201 in 22…
[ad_2]
Source story
